Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2011 Nov 4;11(1):154–164. doi: 10.1158/1535-7163.MCT-11-0606

Figure 6. Effect of the combinatorial treatment with gefitinib and MK-2206 on tumor growth in an intracranial glioma model.

Figure 6

The human glioma cells LN229 (1 × 105 cells in 15 μl of DMEM medium) were injected into the brains of 6-week-old male BALB/c nude mice at 4 mm depth under anesthesia with chloralic hydras (4%, 2ml/kg, ip). Three days after tumor cell implantation, mice were randomly divided into four groups (15 mice/group). Treatments were begun on day 4, according to the following regimens: gefitinib, 80 mg/kg, p.o., 5 consecutive days; MK-2206, 100 mg/kg, p.o., three times per week for 2 weeks; gefitinib + MK-2206, same as above; control, 10% DMSO in saline, p.o. (A) The kaplan-Meier survival curves, n = 10; gefitinib + MK-2206 vs. gefitinib, p = 0.0155, log-rank statistic analysis; (B) At day 17 after tumor cell implantation, the mice were euthanized, and the brains were fixed in 10% buffered formalin, embedded in paraffin, and then stained with hematoxillin-eosin (H&E). The images shown are the representative of 5 mice from each group.